Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program

Pfizer Inc. (NYSE:PFE) and Citibank have agreed to work together in the acceleration of share repurchase, which will involve buying back of Pfizer’s common stock. According to active Wall St. blog coverage the collaboration, which is at the value of $5 billion has already been filed with the Securities Exchange Commission after being signed on February 02, 2017.

Let’s Explore The Conditions And The Environment Surrounding The Duo’s Move

First, the agreement states that an approximation of close to 126 million of Pfizer Inc. (NYSE:PFE)’s shares will be repurchased. It is likely that both Citibank and Pfizer may have to deliver additional common stock shares to each other and better still Pfizer may opt to make cash payment. As a part of a hastened share repurchase agreement, Pfizer had earlier acquired approximately 136 million shares of Pfizer’s common stock with Goldman, Sachs & Co.

Pfizer PFE pharmaceutical stock

pio3 /

Apparently, the drug maker has been undertaking numerous steps in an effort to enlarge the shareholding value and improve business performance. Some of the significant steps include improvement of product portfolio, organizational restructuring, increased dividend payouts, and strategic acquisitions among others.

Reorganization involved merging its Innovative Pharmaceutical and Consumer Healthcare operations into one business unit. On the other hand, a very notable acquisition was that of Hospira, Inc.(NYSE:HSP) in September 2015 at a cost of $16.1 billion, Bamboo Therapeutics Inc. in August 2016 for $150 million and Anacor Pharmaceuticals Inc (NASDAQ:ANAC) in June 2016 for roughly $5.2 billion.

Into The Future Plans Of Pfizer

The Company has so far obtained an operational growth of 11%, which resulted from the full year revenue of $52.8 billion for 2016. For the313th consecutive quarterly, Pfizer Inc. (NYSE:PFE) will also be paying out a dividend of $0.32 for Q1 FY17 on December 13, 2016. The dividend is payable on March 01, 2017.

Having shared its financial guidance for FY17 the company is also in expectation of obtaining revenues within the range of $52 billion-$54 billion. It’s all clear that the Pfizer has been putting its acts together. Meanwhile, Pfizer’s stock was trading at $32.23 witnessing an increase of $0.14 or 0.44%.

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.